The Food and Drug Administration’s decision to delay its decision on Biogen’s aducanumab has prompted additional questions about the drugmaker’s evidence. The FDA says it will be reviewing “additional analyses and clinical data” during the next three months. (STAT)

Horizon announced it will buy Viela Bio for $3 billion. The acquisition brings Viela’s drug Uplizna to Horizon’s rare disease pipeline. (Endpoints News)

The European Union has decided to allow member states to restrict COVID-19 vaccine exports if the vaccine maker has not met its contracts within the EU. Some experts are calling the decision “highly problematic.” (CNBC Weekly)

Pregnant women are questioning whether they should take a COVID-19 vaccine, as there is currently no data on the risk it may pose to expectant mothers. Pregnant women weren’t included in Pfizer’s and Moderna’s vaccine safety trials. (The Wall Street Journal)

The Biden administration will delay one of former President Trump’s drug pricing proposals by a year. The policy, which was scheduled to be implemented in January 2022, would stop drugmakers and middlemen from negotiating rebates. (STAT)